Rehabilitation of adaptive immunity and regeneration of beta cells

Trends in Biotechnology

Volumn 24, Issue 11, 2006, Pages 516-522

  Pasquali, Lorenzo ^a   Fan, Yong ^a   Trucco, Massimo ^a   Ringquist, Steven ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASES; BETA CELLS; ENDOCRINE PANCREAS; TYPE 1 DIABETES (T1D);

DISEASES; DRUG THERAPY; GENETIC ENGINEERING; IMMUNOLOGY; INSULIN;

CELLS;

IMMUNOSUPPRESSIVE AGENT; INSULIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; CELL BASED GENE THERAPY; CELL REGENERATION; CELLULAR IMMUNITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

ANIMALS; BONE MARROW TRANSPLANTATION; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; GENE THERAPY; HLA-DQ ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, ACTIVE; INSULIN-SECRETING CELLS; MODELS, MOLECULAR; REGENERATION;

EID: 33749856483     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2006.08.007     Document Type: Review

References (86)

1. Ringquist S., and Trucco M. Regenerative medicine for diabetes treatment. Discovery Medicine 5 (2005) 142-147
2. Bach J.F. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. Rev. 15 (1994) 516-542
3. Genuth S. Application of the diabetes control and complications trial. In: LeRoith D., Taylor S.I., and Olefsky J.M. (Eds). Diabetes Mellitus, A Fundamental and Clinical Text. 3rd edn (2004), J.B. Lippincott 645-657
4. Shapiro A.M.J., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343 (2000) 230-238
5. Hirshberg B., et al. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression. Diabetes Care 26 (2003) 3288-3295
6. Ryan E.A., et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 51 (2002) 2148-2157
7. Ryan E.A., et al. Five-year follow-up after clinical islet transplantation. Diabetes 54 (2005) 2060-2069
8. Ricordi C., et al. In vivo effect of FK506 on human pancreatic islets. Transplantation 52 (1991) 519-526
9. Tamura K., et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic β-cell. Transplantation 59 (1995) 1606-1615
10. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 23 (2000) 101-113
11. Bell E., et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 52 (2003) 2731-2739
12. Rother K.I., and Harlan D.M. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J. Clin. Invest. 114 (2004) 877-883
13. Inada A., et al. How can we get more beta cells?. Curr. Diab. Rep. 6 (2006) 96-101
14. Bonner-Weir S., and Weir G.C. New sources of pancreatic beta-cells. Nat. Biotechnol. 23 (2005) 857-861
15. Borgens R.B. Mice regrow the tips of their foretoes. Science 217 (1982) 747-750
16. Singer M., et al. Open finger tip healing and replacement after distal amputation in rhesus monkey with comparison to limb regeneration in lower vertebrates. Anat. Embryol. (Berl.) 177 (1987) 29-36
17. Douglas B.S. Conservative management of guillotine amputation of the finger in children. Aust. Paediatr. J. 8 (1972) 86-89
18. Illingworth C.M. Trapped fingers and amputated finger tips in children. J. Pediatr. Surg. 9 (1974) 853-858
19. Wagers A.J., and Weissman I.L. Plasticity of adult stem cells. Cell 116 (2004) 639-648
20. Brockes J.P., and Kumar A. Appendage regeneration in adult vertebrates and implications for regenerative medicine. Science 310 (2005) 1919-1923
21. Reddien P.W., and Sanchez Alvarado A. Fundamentals of planarian regeneration. Annu. Rev. Cell Dev. Biol. 20 (2004) 725-757
22. Fernandes A., et al. Differentiation of new insulin-producing cells is induced by injury in adult pancreatic islets. Endocrinology 138 (1997) 1750-1762
23. Finegood D.T., et al. Prior streptozotocin treatment does not inhibit pancreas regeneration after 90% pancreatectomy in rats. Am. J. Physiol. 276 (1999) E822-E827
24. Movassat J., and Portha B. Beta-cell growth in the neonatal Goto-Kakisaki rat and regeneration after treatment with streptozotocin at birth. Diabetologia 42 (1999) 1098-1106
25. Li L., et al. Activin A and betacellulin: effect on regeneration of pancreatic beta-cells in neonatal streptozotocin-treated rats. Diabetes 53 (2004) 608-615
26. Dor Y., et al. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429 (2004) 41-46
27. Georgia S., and Bhushan A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. J. Clin. Invest. 114 (2004) 963-968
28. Seaberg R.M., et al. Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat. Biotechnol. 22 (2004) 1115-1124
29. Suzuki A., et al. Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. Diabetes 53 (2004) 2143-2152
30. Gershengorn M.C., et al. Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 306 (2004) 2261-2264
31. Bonner-Weir S., et al. The pancreatic ductal epithelium serves as a potential pool of progenitor cells. Pediatr. Diabetes 5 (2004) 16-22
32. Hao E., et al. Beta-cell differentiation from nonendocrine epithelial cells of the adult human pancreas. Nat. Med. 12 (2006) 310-316
33. Butler A.E., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
34. Meier J.J., et al. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?. Diabetologia 48 (2005) 2221-2228
35. Meier J.J., et al. Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. Diabetologia 49 (2006) 1838-1844
36. Scholin A., et al. Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in type 1 diabetes. Diabet. Med. 21 (2004) 447-455
37. Scholin A., et al. Factors predicting clinical remission in adult patients with type 1 diabetes. J. Intern. Med. 245 (1999) 155-162
38. Chase H.P., et al. Redefining the clinical remission period in children with type 1 diabetes. Pediatr. Diabetes 5 (2004) 16-19
39. Karges B., et al. Complete long-term recovery of beta-cell function in autoimmune type 1 diabetes after insulin treatment. Diabetes Care 27 (2004) 1207-1208
40. Karges B., et al. Immunological mechanisms associated with long-term remission of human type 1 diabetes. Diabetes Metab. Res. Rev. 22 (2006) 184-189
41. Ilic S., et al. Is the paradoxical first trimester drop in insulin requirement due to an increase in C-peptide concentration in pregnant type 1 diabetic women?. Diabetologia 43 (2000) 1329-1336
42. Meier J.J., et al. The potential for stem cell therapy in diabetes. Pediatr. Res. 59 (2006) 65R-73R
43. Todd J.A., et al. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329 (1987) 599-604
44. Morel P.A., et al. Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 8111-8115
45. Dorman J., et al. Worldwide differences in the incidence of type I diabetes are associated with amino acid variation at position 57 of the HLA-DQ beta chain. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 7370-7374
46. Trucco M. To be, or not to be Asp 57, that is the question. Diabetes Care 15 (1992) 705-715
47. McDevitt H. Closing in on type 1 diabetes. N. Engl. J. Med. 345 (2001) 1060-1061
48. Lee K.L., et al. Structure of a human insulin peptide/HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat. Immunol. 2 (2001) 501-507
49. Trucco M., and Giannoukakis N. MHC tailored for diabetes cell therapy. Gene Ther. 12 (2005) 553-554
50. Ettinger R.A., et al. Allelic variation in key peptide-binding pockets discriminates between closely related diabetes-protective and diabetes-susceptible HLA-DQB1*06 alleles. J. Immunol. 176 (2006) 1988-1998
51. Acha-Orbea H., and McDevitt H.O. The first external domain of the nonobese diabetic mouse class II I-A β chain is unique. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 2435-2439
52. Lund T., et al. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenic encoding modified I-A β-chain or normal I-E α-chain. Nature 345 (1990) 727-729
53. Parish N., et al. The effect of bone marrow and thymus chimerism between non-obese diabetic (NOD) and NOD-E transgenic mice, on the expression and prevention of diabetes. Eur. J. Immunol. 23 (1993) 2667-2675
54. Ikehara S., et al. Prevention of type 1 diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 7743-7747
55. Beilhack G.F., et al. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 52 (2003) 59-68
56. Nikolic B., et al. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes 53 (2004) 376-383
57. Zorina T.D., et al. Recovery of endogenous beta cell function in the NOD model of autoimmune diabetes. Stem Cells 21 (2003) 377-388
58. Ogawa N., et al. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53 (2004) 1700-1705
59. Kodama S., et al. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302 (2003) 1223-1227
60. Chong A.S., et al. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 311 (2006) 1774-1775
61. Nishio J., et al. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 311 (2006) 1775-1778
62. Suri A., et al. Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science 311 (2006) 1778-1780
63. Hess D., et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol. 21 (2003) 763-770
64. Melton D.A. Reversal of type 1 diabetes in mice. N. Engl. J. Med. 355 (2006) 89-90
65. Shehadeh N., et al. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 343 (1994) 706-707
66. Singh B., and Elliot J.F. Can progression of IDDM be prevented in newly diagnosed patients by BCG immunotherapy?. Diabetes Metab. Rev. 13 (1997) 320-321
67. von Herrath M., and Homann D. Islet regeneration needed for overcoming autoimmune destruction considerations on the pathogenesis of type 1 diabetes. Pediatr. Diabetes 5 (2004) 23-28
68. Sutherland D.E., et al. Twin-to-twin pancreas transplantation: reversal and re-enactment of the pathogenesis of type I diabetes. Trans. Assoc. Am. Physicians 97 (1984) 80-87
69. Starzl T.E., et al. Systemic chimerism in human female recipients of male livers. Lancet 340 (1992) 876-877
70. Li H., et al. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J. Immunol. 156 (1996) 380-388
71. Zorina T.D., et al. Distinct characteristics and features of allogeneic chimerism in the NOD mouse model of autoimmune diabetes. Cell Transplant. 11 (2002) 113-123
72. Hutchings P.R., and Cooke A. The transfer of autoimmune diabetes in NOD mice can be inhibited or accelerated by distinct cell populations present in normal splenocytes taken from young males. J. Autoimmun. 3 (1990) 175-185
73. Rood P.P., et al. Facilitating physiologic self-regeneration: a step beyond islet cell replacement. Pharm. Res. 23 (2006) 227-242
74. Tian C., et al. Prevention of type 1 diabetes by gene therapy. J. Clin. Invest. 114 (2004) 969-978
75. Machen J., et al. Antisense oligonucleotides downregulating co-stimulation confer diabetes-preventive properties to NOD dendritic cells. J. Immunol. 173 (2004) 4331-4341
76. + T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes 55 (2006) 158-170
77. Greenbaum C.J. Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials. Clin. Immunol. 104 (2002) 97-104
78. Trucco M. Regeneration of the pancreatic beta cell. J. Clin. Invest. 115 (2005) 5-12
79. Steffes M.W., et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26 (2003) 832-836
80. Keymeulen B., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352 (2005) 2598-2608
81. Wang Z., et al. Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes. Diabetes 55 (2006) 875-884
82. Suarez-Pinzon W.L., et al. Combination therapy with epidermal growth factor and gastrin increases β-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 54 (2005) 2596-2601
83. Biason-Lauber A., et al. Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cell regenerative capacity. Diabetologia 48 (2005) 900-905
84. Garcia-Ocana A., et al. Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J. Biol. Chem. 275 (2000) 1226-1232
85. George M., et al. Beta cell expression of IGF-I leads to recovery from type 1 diabetes. J. Clin. Invest. 109 (2002) 1153-1163
86. Guo Y., et al. Pancreatic islet-specific expression of an insulin-like growth factor-I transgene compensates islet cell growth in growth hormone receptor gene deficient mice. Endocrinology 146 (2005) 2602-2609